B7-H3 Expression in Breast Cancer and Brain Metastasis
International Journal of Molecular Sciences · 03.04.2024 · 25 (7) · 3976
DOI: 10.3390/ijms25073976 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.04.2024. Verfasst von Vaibhavi Joshi und 9 weiteren Autor:innen. Beteiligte Einrichtung: UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane 4029, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Brain metastasis is a significant challenge for some breast cancer patients, marked by its aggressive nature, limited treatment options, and poor clinical outcomes. Immunotherapies have emerged as a promising avenue for brain metastasis treatment. B7-H3 (CD276) is an immune checkpoint molecule involved in T cell suppression, which is associated with poor survival in cancer patients. Given the increasing number of clinical trials using B7-H3 targeting CAR T cell therapies, we examined B7-H3 expression across breast cancer subtypes and in breast cancer brain metastases to assess its potential as an interventional target. B7-H3 expression was investigated using immunohistochemistry on tissue microarrays of three clinical cohorts: (i) unselected primary breast cancers (n = 347); (ii) brain metastatic breast cancers (n = 61) and breast cancer brain metastases (n = 80, including a subset of 53 patient-matched breast and brain metastasis cases); and (iii) mixed brain metastases from a range of primary tumours (n = 137). In primary breast cancers, B7-H3 expression significantly correlated with higher tumour grades and aggressive breast cancer subtypes, as well as poorer 5-year survival outcomes. Subcellular localisation of B7-H3 impacted breast cancer-specific survival, with cytoplasmic staining also correlating with a poorer outcome. Its expression was frequently detected in brain metastases from breast cancers, with up to 90% expressing B7-H3. However, not all brain metastases showed high levels of expression, with those from colorectal and renal tumours showing a low frequency of B7-H3 expression (0/14 and 2/16, respectively). The prevalence of B7-H3 expression in breast cancers and breast cancer brain metastases indicates potential opportunities for B7-H3 targeted therapies in breast cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane 4029, Australia.
- MRC Prion Unit at UCL, Institute of Prion Diseases, Courtauld Building, London W1W 7FF, UK.
- Centre for Cancer Biology, Clinical and Health Sciences, University of South Australia & SA Pathology, Adelaide 5001, Australia.
- Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane 4029, Australia.
ORCID-Profile: Vaibhavi Joshi, Kate Beecher, Malcolm Lim, Pascal H G Duijf, Peter T Simpson, Sunil R Lakhani, Amy E McCart Reed
Förderung
- National Health and Medical Research Council
Zitieren
APA
Joshi, V., Beecher, K., Lim, M., Stacey, A., Feng, Y., Jat, P. S., Duijf, P. H. G., Simpson, P. T., Lakhani, S. R., & McCart Reed, A. E. (2024). B7-H3 Expression in Breast Cancer and Brain Metastasis. International Journal of Molecular Sciences, 25(7), 3976. https://doi.org/10.3390/ijms25073976
Vancouver
Joshi V, Beecher K, Lim M, Stacey A, Feng Y, Jat PS, et al. B7-H3 Expression in Breast Cancer and Brain Metastasis. International Journal of Molecular Sciences. 2024;25(7):3976. doi:10.3390/ijms25073976
BibTeX
@article{Joshi2024,
author = {Joshi, Vaibhavi and Beecher, Kate and Lim, Malcolm and Stacey, Andrew and Feng, Yufan and Jat, Parmjit S and Duijf, Pascal H G and Simpson, Peter T and Lakhani, Sunil R and McCart Reed, Amy E},
title = {B7-H3 Expression in Breast Cancer and Brain Metastasis},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {7},
pages = {3976},
doi = {10.3390/ijms25073976}
}
EUVIMED